MediPharm Labs (LABS) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue reached $9.8M, up 15% year-over-year, with international medical cannabis revenue growing 37% and representing 36% of total revenue.

• Adjusted EBITDA improved to negative $743K from negative $2.4M in Q3 2023, reflecting cost reductions and operational efficiencies.

• Gross profit margin rose to 32%, a 29% improvement year-over-year, driven by favorable product mix and production efficiencies.

• All convertible debt was fully repaid in Q3 2024, leaving the company debt-free and with $13M in cash.

• International expansion advanced with strong sales in Australia and Germany, and regulatory progress in the UK, Brazil, and New Zealand.

Financial highlights

• Net revenue for Q3 2024 was $9.8M, up from $8.5M in Q3 2023.

• Gross profit for Q3 2024 was $3.1M, up from $2.4M in Q3 2023.

• Operating expenses for Q3 2024 were $5.4M, down from $6.1M in Q3 2023.

• Adjusted EBITDA for Q3 2024 was negative $743K, a significant improvement from negative $2.4M in Q3 2023.

• Cash balance at quarter-end was $13M.

Outlook and guidance

• Management expects continued progress toward profitability in 2025, supported by international growth and cost efficiencies.

• Ongoing regulatory registrations in new international markets are expected to drive future revenue.

• Facility rationalization and cost-saving initiatives are anticipated to support long-term sustainable growth.